Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
Norfloxacin is a new organic acid antimicrobic with an expanded spectrum that includes Staphylococcus spp, most Pseudomonas spp, Acinetobacter calcoaceticus ssp anitratus, some streptococci, as well as nearly all enteric bacilli. The drug appears to be bactericidal. Its expanded spectrum suggests that it should be tested separately by disk diffusion or other susceptibility testing methods. Tentative norfloxacin disk test quality control limits were derived from the results of a multi-laboratory study: Escherichia coli, 28-36 mm; S. aureus, 17-28 mm, and Pseudomonas aeruginosa, 22-29 mm.
D000150:Acinetobacter / Q000187:drug effects; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002937:Cinoxacin / Q000494:pharmacology; D004338:Drug Combinations / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D008826:Microbial Sensitivity Tests / Q000592:standards; D009268:Nalidixic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D009643:Norfloxacin; D010093:Oxolinic Acid / Q000494:pharmacology; D011549:Pseudomonas / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011786:Quality Control; D012015:Reference Standards; D013211:Staphylococcus aureus / Q000187:drug effects; D013420:Sulfamethoxazole / Q000494:pharmacology; D014295:Trimethoprim / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D009268:Nalidixic Acid; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D010093:Oxolinic Acid; D002937:Cinoxacin; D009643:Norfloxacin